Our Pricing

Mounjaro vs Wegovy UK Comparison

Published on: June 03, 2026

When researching a mounjaro vs wegovy uk comparison, understanding the clinical differences between tirzepatide and semaglutide is essential for making an informed choice. At Cured Pharmacy, our UK-registered clinical team provides expert guidance on both treatments, with transparent pricing from £135.00 and free online consultations completed in under three minutes.

How Mounjaro and Wegovy Work Differently

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA in the UK [1]. This dual-action mechanism activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, regulating appetite, slowing gastric emptying, and improving insulin sensitivity. Wegovy, by contrast, contains semaglutide, which targets only the GLP-1 receptor pathway.

In the SURPASS-2 head-to-head trial comparing tirzepatide directly with semaglutide 1mg, patients receiving the highest tirzepatide dose (15mg) achieved an average body weight reduction of 12.4kg compared to 6.2kg with semaglutide over 40 weeks [1]. This dual-receptor activation appears to produce greater metabolic effects than single-pathway GLP-1 agonists alone.

Both medications are administered as once-weekly subcutaneous injections using pre-filled pens. All prescription weight loss treatments available at Cured Pharmacy require clinical assessment by a UK prescriber to ensure suitability and safety.

Clinical Trial Results: Mounjaro vs Wegovy Effectiveness

The SURMOUNT-1 trial demonstrated that patients taking Mounjaro 15mg achieved an average weight reduction of 22.5% of their initial body weight over 72 weeks [2]. In comparison, the STEP-1 trial showed Wegovy 2.4mg produced an average weight reduction of 14.9% over 68 weeks [3]. Both trials enrolled adults with obesity or overweight with weight-related comorbidities.

Importantly, individual results vary considerably based on adherence to lifestyle modifications, baseline metabolic health, and concurrent medical conditions. In the SURPASS-3 trial, approximately 63% of participants on the highest Mounjaro dose achieved at least 20% weight reduction, compared to 30% on placebo [2]. For Wegovy, the STEP-1 trial reported that 50.5% of participants achieved at least 15% weight reduction [3].

Your UK prescriber will assess your medical history, current medications, BMI, and weight loss goals to determine which treatment may be most appropriate. Neither medication guarantees specific outcomes, and both work most effectively when combined with a reduced-calorie diet and increased physical activity.

Time to Results

Most patients begin noticing appetite reduction within the first two weeks of starting either Mounjaro or Wegovy. Measurable weight loss typically becomes evident after 4-8 weeks, with progressive reductions continuing throughout the dose escalation period. Both medications use gradual dose titration schedules to minimise gastrointestinal side effects whilst optimising therapeutic response.

Dosing Schedules and Administration

Mounjaro follows a four-step dose escalation: starting at 2.5mg weekly for four weeks, then increasing to 5mg, 7.5mg, 10mg, 12.5mg, and potentially 15mg based on individual response and tolerability [1]. Wegovy uses a similar graduated approach: 0.25mg weekly for four weeks, then 0.5mg, 1mg, 1.7mg, and finally the maintenance dose of 2.4mg [3].

Both treatments are administered via subcutaneous injection into the abdomen, thigh, or upper arm using pre-filled single-dose pens. The KwikPen devices used for Mounjaro and the FlexTouch pens for Wegovy are designed for self-administration at home. Your UK prescriber will provide detailed injection technique guidance during your consultation.

If you miss a dose of either medication, the timing of your next injection depends on how many days have elapsed. For both Mounjaro and Wegovy, if fewer than four days have passed, take the missed dose as soon as possible. If more than four days have passed, skip the missed dose and resume your normal schedule. Never double doses to compensate for missed injections.

Storage Requirements

Both Mounjaro and Wegovy must be refrigerated between 2°C and 8°C before first use. Once in use, pens may be stored at room temperature (up to 30°C) for up to 21 days. Protect both medications from direct sunlight and never freeze. Always check the solution is clear and colourless before injecting—discard if cloudy or discoloured.

Side Effects and Tolerability Profile

The most common side effects for both Mounjaro and Wegovy are gastrointestinal: nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [1][3]. These effects typically occur during dose escalation and often diminish as your body adapts to the medication. In clinical trials, nausea was reported by approximately 33% of Mounjaro users and 44% of Wegovy users, though most cases were mild to moderate [2][3].

Less common but more serious potential side effects include pancreatitis, gallbladder problems, hypoglycaemia (particularly in patients taking diabetes medications), and changes in vision. Both medications carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans [1][3].

Discontinuation rates due to adverse events were approximately 6.2% for Mounjaro and 7.0% for Wegovy in their respective pivotal trials [2][3]. Your UK prescriber will review your complete medical history to identify any contraindications, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Cost Comparison and Value at Cured Pharmacy

At Cured Pharmacy, Mounjaro is available from £124.99 and Wegovy from £135.00, with final pricing determined by your prescribed dose following clinical assessment. These transparent upfront prices include your medication, UK prescriber consultation, and discreet delivery to your door. We guarantee the lowest prices in the UK for genuine, MHRA-licensed weight loss treatments.

When comparing overall value, consider both the per-pen cost and the clinical effectiveness data. Whilst Mounjaro carries a higher initial price point, the superior average weight reduction observed in clinical trials may represent better value for some patients. Conversely, Wegovy's lower starting price and well-established safety profile make it an excellent option for cost-conscious patients.

All prescription weight loss medications at Cured Pharmacy require a free online consultation with a UK-registered prescriber, completed in under three minutes. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all clinical services to ensure you receive safe, appropriate treatment tailored to your individual circumstances.

Additional Weight Loss Options

Beyond Mounjaro and Wegovy, Cured Pharmacy offers Saxenda (liraglutide) as a daily injection option, and oral treatments including Orlistat and Xenical for patients who prefer non-injectable alternatives. Your prescriber will discuss all suitable options during your consultation based on your medical history, preferences, and treatment goals.

Making Your Choice: Which Treatment Is Right for You?

The decision between Mounjaro and Wegovy depends on multiple factors: your weight loss goals, budget, tolerance for potential side effects, injection frequency preferences, and underlying health conditions. Patients seeking maximum weight reduction based on current trial data may prefer Mounjaro's dual-receptor mechanism, whilst those prioritising established safety data and lower cost may opt for Wegovy.

Both medications require commitment to lifestyle modifications for optimal results. Clinical trials demonstrating significant weight loss all included dietary counselling and increased physical activity components [2][3]. Neither medication is a standalone solution—they work as adjuncts to comprehensive weight management programmes.

Your UK prescriber will conduct a thorough assessment of your BMI, medical history, current medications, and any contraindications before recommending the most appropriate treatment. Some patients may not be suitable candidates for GLP-1 or dual-agonist therapies, in which case alternative options like Orlistat or Saxenda may be more appropriate. Start your free online consultation at Cured Pharmacy today to receive personalised expert guidance from our UK-registered clinical team.

Scientific References

1. Frias, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
2. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
3. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss medications work most effectively when combined with a reduced-calorie diet and increased physical activity.